Yes, completely free. QuickRx Specialty Pharmacy provides free enrollment and support for all Bosulif (bosutinib) copay assistance programs including manufacturer copay cards and patient assistance programs. We never charge service fees for helping patients access medication savings.

What’s included at no cost:

• Application assistance for Bosulif (bosutinib) manufacturer copay cards
• Generic bosutinib pricing and availability consultation
• Insurance verification and benefit checks
• Prior authorization support when needed
• Foundation grant applications for leukemia treatment
• Ongoing monitoring to ensure continuous savings
• Prescription coordination and specialty medication delivery

Bosulif (bosutinib) savings programs available:

For patients with commercial insurance, manufacturer copay cards for Bosulif can significantly reduce your out-of-pocket costs. Generic bosutinib may also offer substantial savings depending on your insurance coverage.

For Medicare and Medicaid patients, foundation-based assistance programs provide grants that help cover medication expenses. These programs are also free to apply for with QuickRx’s help. Generic bosutinib may be a more affordable option for some Medicare patients.

For uninsured patients, manufacturer patient assistance programs may provide Bosulif (bosutinib) at no cost or significantly reduced prices based on financial need. Generic bosutinib is another cost-effective alternative we can help you access.

Our team’s only goal is to make Bosulif (bosutinib) more affordable so you can focus on managing your chronic myeloid leukemia without financial stress. Contact QuickRx at (917) 830-2525 or (800) 496-6111 to get started today, or visit our copay assistance page for more information.

Eligibility depends on your insurance type, medical diagnosis, and financial circumstances. Here’s how QuickRx makes enrollment simple:

Step 1: Reach out to QuickRx
Call (917) 830-2525 or toll-free (800) 496-6111, or complete our confidential online enrollment form.

Step 2: Insurance Review
Our team verifies your coverage and identifies which copay assistance programs match your insurance type.

Step 3: Qualification Assessment
We review eligibility requirements for each program—income limits (for some programs), insurance type, and diagnosis confirmation.

Step 4: Application Support
We handle all paperwork and follow up with each program to ensure timely approval.

General eligibility by insurance type:

Commercial Insurance: Most patients with employer-sponsored or marketplace insurance qualify for Bosulif manufacturer copay cards with no income restrictions.

Medicare Part D: Foundation grants available for eligible patients. Income limits vary by foundation (typically up to 500% of federal poverty level).

Medicaid: Foundation grants available to cover state-required copays. Income-based eligibility applies.

No Insurance: Patient assistance programs provide free medication for eligible patients based on household income (typically up to 400-500% of federal poverty level).

Savings vary by insurance type and the assistance programs you qualify for. QuickRx works to maximize your savings through all available programs including generic bosutinib options.

Potential Bosulif (bosutinib) copay assistance savings:

With commercial insurance, manufacturer copay cards can significantly reduce out-of-pocket costs for Bosulif. The amount of savings depends on your insurance plan’s copay or coinsurance amount and the specific program benefit limits. Generic bosutinib may offer additional savings opportunities.

With Medicare or Medicaid, foundation grants and patient assistance programs help cover medication costs that Medicare doesn’t pay. Savings vary based on the foundation’s annual benefit caps and your specific financial situation.

For uninsured patients, manufacturer patient assistance programs may provide Bosulif (bosutinib) at no cost if you meet income requirements. Generic bosutinib typically costs substantially less than brand name medication.

Real savings examples:

Without assistance, Bosulif (bosutinib) can cost thousands of dollars per month. With copay assistance programs, many commercially insured patients reduce their costs to minimal amounts. Medicare patients often receive grants that cover significant portions of their medication expenses. Uninsured patients who qualify for patient assistance programs may receive free medication.

Why choose QuickRx for Bosulif (bosutinib) copay assistance:

QuickRx doesn’t stop at finding one savings program—we identify every program you qualify for and stack benefits when possible. We also provide ongoing support to ensure your savings continue year after year. Our team monitors your benefit balances and handles annual renewals automatically.

No, federal law prohibits Medicare beneficiaries from using manufacturer copay cards. However, QuickRx connects Medicare patients to alternative financial assistance programs specifically designed for government insurance beneficiaries.

Why Medicare patients can’t use copay cards:

The Anti-Kickback Statute prevents drug manufacturers from offering copay cards to Medicare patients because these programs could be considered illegal inducements to use specific medications. This regulation applies to all Medicare Part D plans, Medicare Advantage prescription drug plans, and any federal healthcare program.

Financial assistance alternatives for Medicare patients:

Independent foundation grants: Nonprofit patient assistance foundations provide grants to help Medicare beneficiaries pay for chronic myeloid leukemia treatments including Bosulif (bosutinib). These foundations operate independently from pharmaceutical manufacturers and comply with federal regulations.

Manufacturer patient assistance programs: Some pharmaceutical companies offer income-based patient assistance programs that provide free or low-cost medication to eligible Medicare patients who meet financial criteria.

Generic bosutinib options: Medicare patients may find generic bosutinib more affordable than brand name Bosulif, with lower copays under their Part D coverage.

How QuickRx helps Medicare patients with Bosulif (bosutinib):

Our team specializes in navigating Medicare coverage for specialty medications. We identify all available foundation grants, coordinate applications, and monitor grant availability throughout the year. We also help with Medicare Part D plan selection during annual enrollment to find the most affordable coverage for your chronic myeloid leukemia treatment.

Call (917) 830-2525 or (800) 496-6111 to speak with a Medicare specialist about Bosulif (bosutinib) financial assistance options, or contact us online.

Approval times vary by program type, but QuickRx works to expedite your Bosulif (bosutinib) copay assistance enrollment as quickly as possible.

Typical approval timeframes:

Manufacturer copay cards (commercial insurance): Often approved within 24-48 hours. Many programs provide instant approval online, and QuickRx can typically apply your copay card benefits to your first prescription immediately.

Foundation grants (Medicare/Medicaid patients): Usually take 1-3 weeks for approval, depending on the foundation’s application review process and funding availability. Some foundations process applications within days during periods of strong funding.

Patient assistance programs (uninsured patients): Typically require 2-4 weeks for approval as manufacturers verify income eligibility and prescription details. Rush processing may be available for urgent medication needs.

How QuickRx accelerates your approval:

Our specialty pharmacy team knows which programs have the fastest approval processes and submits complete, accurate applications the first time to avoid delays. We follow up proactively with programs to expedite processing when possible. For urgent situations, we can often arrange temporary supplies while your assistance applications are pending.

What you can do while waiting:

While your Bosulif (bosutinib) copay assistance application is being processed, QuickRx can help explore generic bosutinib options that may be more affordable through your current insurance coverage. We can also coordinate with your healthcare provider to ensure you have access to medication without interruption.

Don’t delay treatment due to cost concerns. Call QuickRx at (917) 830-2525 or toll-free (800) 496-6111 or start your Bosulif (bosutinib) copay assistance application today. The sooner you apply, the sooner you can start saving.

Bosulif (bosutinib) is a prescription medication used to treat chronic myeloid leukemia (CML), a type of blood cancer that affects white blood cells and bone marrow. Bosulif is a targeted therapy called a tyrosine kinase inhibitor (TKI) that blocks specific proteins responsible for cancer cell growth.

FDA-approved uses for Bosulif (bosutinib):

Bosulif is approved for adults with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic phase CML as well as for chronic, accelerated, or blast phase Ph+ CML in patients who have resistance or intolerance to prior TKI therapy.

How Bosulif (bosutinib) works:

Chronic myeloid leukemia is caused by an abnormal chromosome called the Philadelphia chromosome, which creates an abnormal protein (BCR-ABL) that tells cells to grow and divide uncontrollably. Bosulif is a BCR-ABL tyrosine kinase inhibitor that blocks this abnormal protein, helping to slow or stop the growth of CML cells.

Unlike traditional chemotherapy that affects all rapidly dividing cells, Bosulif is a targeted therapy that specifically blocks the proteins driving CML cell growth. This targeted approach often results in fewer side effects compared to traditional chemotherapy.

Treatment phases of CML:

• Chronic phase: The earliest and most common stage, where most patients are diagnosed. Bosulif is highly effective at controlling chronic phase CML.
• Accelerated phase: When CML becomes more aggressive with increased blast cells. Bosulif can be used when other TKIs have failed.
• Blast phase (blast crisis): The most advanced stage where CML behaves like acute leukemia. Bosulif may be an option for patients who cannot tolerate other TKIs.

Who prescribes Bosulif (bosutinib):

Bosulif is prescribed by hematologists or oncologists who specialize in treating blood cancers. Your doctor will determine if Bosulif is the right treatment for your specific type and stage of CML based on your medical history, prior treatments, and genetic testing results.

QuickRx Specialty Pharmacy works closely with your healthcare team to coordinate Bosulif (bosutinib) prescriptions, insurance coverage, and copay assistance programs. Call (917) 830-2525 or (800) 496-6111 to learn more about accessing affordable Bosulif treatment.

Like all medications, Bosulif (bosutinib) can cause side effects, though not everyone experiences them. Understanding potential side effects helps you know what to monitor and when to contact your healthcare provider.

Most common side effects of Bosulif (bosutinib):

The most frequently reported side effects include:

• Diarrhea (occurs in many patients, especially during the first few months of treatment)
• Nausea and vomiting
• Abdominal pain
• Rash or skin reactions
• Fatigue and weakness
• Low blood cell counts (thrombocytopenia, anemia, neutropenia)
• Elevated liver enzymes (detected through blood tests)
• Headache
• Joint or muscle pain
• Respiratory infections

Serious side effects requiring immediate medical attention:

Gastrointestinal toxicity: Severe diarrhea, vomiting, or abdominal pain can lead to dehydration and requires prompt medical care. Your doctor may adjust your dose or prescribe medications to manage these symptoms.

Liver problems: Bosulif can cause elevated liver enzymes or hepatotoxicity. Your healthcare provider will monitor your liver function through regular blood tests. Contact your doctor immediately if you experience yellowing of skin or eyes (jaundice), dark urine, severe abdominal pain, or unusual fatigue.

Low blood counts (myelosuppression): Bosulif can reduce white blood cells, red blood cells, and platelets, increasing risks of infection, anemia, and bleeding. Your doctor will monitor your blood counts regularly. Report any signs of infection (fever, chills), unusual bruising or bleeding, or severe fatigue.

Fluid retention: Some patients develop edema (swelling) in the legs, feet, or around the eyes. Severe fluid retention can cause difficulty breathing and requires medical evaluation.

Heart problems: Rarely, Bosulif may cause heart rhythm changes (QT prolongation) or other cardiac effects. Your doctor may perform electrocardiograms (ECGs) to monitor heart function.

Managing Bosulif (bosutinib) side effects:

Most side effects are manageable with dose adjustments, supportive medications, or timing modifications. Your healthcare team can prescribe anti-diarrheal medications, anti-nausea drugs, or adjust your Bosulif dose to minimize side effects while maintaining treatment effectiveness.

Taking Bosulif with food can help reduce gastrointestinal side effects. Staying well-hydrated and maintaining good nutrition also helps manage treatment-related symptoms.

When to contact your doctor:

Report any new or worsening symptoms to your healthcare provider, especially severe diarrhea, vomiting, signs of infection, unusual bleeding or bruising, severe fatigue, chest pain, or difficulty breathing.

Bosulif (bosutinib) is taken by mouth once daily with food. Following your doctor’s dosing instructions and taking Bosulif consistently helps maximize treatment effectiveness while minimizing side effects.

Standard Bosulif (bosutinib) dosing:

The typical adult dose for newly diagnosed chronic phase CML is 400 mg once daily taken with food. For patients with CML who have resistance or intolerance to prior therapy, the usual dose is 500 mg once daily with food.

Your healthcare provider will determine the right dose based on your specific diagnosis, prior treatments, and how you respond to therapy. Doses may be adjusted based on blood counts, side effects, or liver function.

Important administration instructions:

Take with food: Always take Bosulif with a meal. Taking it with food significantly reduces gastrointestinal side effects like nausea and diarrhea, and also helps your body absorb the medication properly.

Swallow tablets whole: Do not crush, break, or chew Bosulif tablets. If you have difficulty swallowing, talk to your healthcare provider about alternatives.

Take at the same time each day: Maintaining a consistent schedule helps ensure steady medication levels in your body and makes it easier to remember your dose.

If you miss a dose: If you forget a dose and it’s within 12 hours of your usual time, take it with food as soon as you remember. If more than 12 hours have passed, skip the missed dose and take your next dose at the regular time. Never double up doses to make up for a missed one.

Dose adjustments for side effects or blood counts:

Your doctor may temporarily stop Bosulif or reduce your dose if you develop significant side effects or if your blood counts drop too low. Once side effects improve or blood counts recover, your doctor may restart Bosulif at the same or a lower dose.

Common dose modifications include reducing from 500 mg to 400 mg daily, from 400 mg to 300 mg daily, or from 300 mg to 200 mg daily based on individual tolerance and response.

Yes, generic bosutinib is FDA-approved and is considered bioequivalent to brand name Bosulif. Generic bosutinib contains the same active ingredient at the same strength and works the same way in your body as the brand name medication.

What does bioequivalent mean?

When the FDA approves a generic medication, it must demonstrate that it is bioequivalent to the brand name drug. This means:

• The generic contains the same active ingredient (bosutinib)
• The generic has the same dosage strength
• The medication is absorbed into the bloodstream at the same rate and to the same extent
• The generic meets the same quality standards for manufacturing, safety, and effectiveness

Cost savings with generic bosutinib:

Generic medications typically cost significantly less than brand name drugs, even when using copay assistance programs. The cost difference can be substantial, especially for patients with Medicare (who cannot use manufacturer copay cards), high-deductible commercial insurance plans, or those paying out-of-pocket.

For Medicare patients: Generic bosutinib may be considerably more affordable under Part D coverage compared to brand name Bosulif, since you’ll pay the generic tier copay rather than the specialty tier copay.

For commercially insured patients: Even with copay cards, your insurance may process claims more affordably with generic bosutinib, which can help you meet deductibles faster and reduce long-term costs.

Should I choose generic or brand name?

Most patients do well on generic bosutinib and benefit from the significant cost savings. However, your healthcare provider will help determine the best option based on your specific situation. Some insurance plans may require you to try the generic version first before covering brand name Bosulif.

QuickRx dispenses both brand and generic bosutinib:

QuickRx Specialty Pharmacy stocks both brand name Bosulif and generic bosutinib. We work with your insurance to determine which option is most affordable and help you access copay assistance regardless of which version you’re prescribed.

Our team can provide pricing comparisons and help you understand your out-of-pocket costs for both brand and generic options. We also coordinate with your healthcare provider if a prescription change is needed to access generic bosutinib.

Bosulif (bosutinib) can interact with many other medications, which may affect how Bosulif works or increase the risk of side effects. It’s critical to tell your healthcare provider and pharmacist about all medications, supplements, and herbal products you’re taking.

Medications that can increase Bosulif levels:

Strong CYP3A inhibitors can significantly increase bosutinib levels in your blood, raising the risk of side effects. These include:

• Antifungal medications: ketoconazole, itraconazole, voriconazole, posaconazole
• Antibiotics: clarithromycin, telithromycin
• HIV medications: ritonavir, indinavir, nelfinavir, saquinavir
• Other medications: nefazodone, conivaptan
• Grapefruit and grapefruit juice also inhibit CYP3A and should be avoided

If you must take a strong CYP3A inhibitor, your doctor may reduce your Bosulif dose or monitor you more closely for side effects.

Medications that can decrease Bosulif effectiveness:

Strong CYP3A inducers can lower bosutinib levels in your blood, potentially reducing its effectiveness against CML. These include:

• Anticonvulsants: phenytoin, carbamazepine, phenobarbital
• Antibiotics: rifampin, rifabutin
• Herbal supplements: St. John’s wort
• Other medications: dexamethasone (long-term use)

Your doctor will typically avoid prescribing these medications with Bosulif when possible, or may need to adjust your Bosulif dose if you must take them.

Proton pump inhibitors (PPIs) and acid reducers:

Medications that reduce stomach acid can decrease bosutinib absorption and effectiveness. These include:

• Proton pump inhibitors (PPIs): omeprazole, esomeprazole, lansoprazole, pantoprazole – avoid if possible
• H2 receptor antagonists: ranitidine, famotidine – can be used with careful timing
• Antacids: should be separated from Bosulif by at least 2 hours

If you need acid-reducing medication, your doctor may recommend alternatives or adjust timing to minimize interaction with Bosulif.

Other important interactions:

Drugs that prolong QT interval: Bosulif may cause heart rhythm changes, and combining it with other QT-prolonging medications increases this risk. Your doctor will monitor your heart rhythm with ECGs if you take these medications together.

P-glycoprotein (P-gp) substrates: Bosulif inhibits P-gp, which can increase levels of medications like digoxin, dabigatran, or colchicine. Your doctor may need to adjust doses of these medications.

What to tell your healthcare team:

Before starting Bosulif, provide your doctor and pharmacist with a complete list of:

• All prescription medications
• Over-the-counter drugs
• Vitamins and supplements
• Herbal products
• Any changes to your medication regimen during Bosulif treatment

QuickRx Specialty Pharmacy conducts thorough drug interaction screening when you fill your Bosulif (bosutinib) prescription. Our pharmacists will contact you and your prescriber if we identify any significant interactions that need to be addressed.

Call (917) 830-2525 or (800) 496-6111 if you have questions about potential drug interactions with Bosulif (bosutinib).

Your healthcare provider will monitor your response to Bosulif (bosutinib) through regular blood tests and bone marrow examinations to ensure the medication is effectively controlling your chronic myeloid leukemia.

Types of treatment responses in CML:

Hematologic response: This is measured through regular blood tests (complete blood count or CBC). Your doctor checks your white blood cell count, platelet count, and red blood cell count. A complete hematologic response means your blood counts have returned to normal ranges.

Cytogenetic response: This is assessed through bone marrow tests that look for the Philadelphia chromosome. A complete cytogenetic response means no Philadelphia chromosome-positive cells are detected in your bone marrow samples.

Molecular response: This is measured through highly sensitive blood tests (quantitative PCR) that detect BCR-ABL transcript levels. A major molecular response means BCR-ABL levels have decreased to very low or undetectable levels.

Monitoring schedule for Bosulif (bosutinib):

Your healthcare provider will typically monitor your response with:

• Blood tests (CBC and chemistry): Every 1-2 weeks initially, then monthly once stable, to monitor blood counts and liver function
• BCR-ABL testing: Every 3 months to assess molecular response
• Bone marrow examination: At baseline, at 3 months, at 6 months, then annually or as needed to assess cytogenetic response
• Electrocardiogram (ECG): At baseline and periodically during treatment to monitor heart rhythm

What response timelines to expect:

For newly diagnosed chronic phase CML: Most patients achieve complete hematologic response within the first 3 months. Cytogenetic responses typically occur within 3-12 months, and molecular responses develop over 12-18 months of treatment.

For treatment-resistant or intolerant CML: Response timelines may vary based on disease stage and prior treatments. Your doctor will establish individualized treatment goals and monitoring schedules.

Signs that Bosulif may not be working:

Contact your healthcare provider if you experience:

• Worsening CML symptoms (unexplained fever, night sweats, weight loss, bone pain)
• Abnormal blood test results showing rising white blood cell counts or worsening blood counts
• Increasing BCR-ABL transcript levels on molecular monitoring
• Development of new mutations in the BCR-ABL gene

Treatment adjustments based on response:

If Bosulif is not achieving adequate response, your doctor may:

• Increase your Bosulif dose (if you’re tolerating the current dose well)
• Switch to a different tyrosine kinase inhibitor
• Add other therapies to your treatment regimen
• Consider more advanced treatment options like stem cell transplantation

Regular monitoring and communication with your healthcare team ensures Bosulif (bosutinib) continues to effectively control your CML over time.

QuickRx Specialty Pharmacy coordinates with your healthcare provider to ensure you have uninterrupted access to Bosulif (bosutinib) and maintains your copay assistance benefits throughout your treatment journey. Call (917) 830-2525 or (800) 496-6111 with any questions about your treatment.

Certain foods, beverages, and activities should be avoided or approached with caution while taking Bosulif (bosutinib) to ensure treatment safety and effectiveness.

Foods and beverages to avoid:

Grapefruit and grapefruit juice: These contain compounds that inhibit the enzyme CYP3A, which breaks down bosutinib in your body. Consuming grapefruit products can significantly increase bosutinib levels in your blood, raising the risk of serious side effects. Avoid all grapefruit products throughout your Bosulif treatment.

Other citrus fruits: While not as potent as grapefruit, Seville oranges (bitter oranges) and pomelos may also affect bosutinib metabolism. Discuss with your healthcare provider whether you need to avoid these fruits.

Alcohol: While there’s no absolute prohibition on alcohol, drinking can worsen certain Bosulif side effects like nausea, vomiting, and liver problems. Limit alcohol consumption and discuss any alcohol use with your healthcare provider, especially if you have liver function changes.

Medications and supplements to avoid or use cautiously:

St. John’s wort: This herbal supplement significantly reduces bosutinib levels and can make your treatment ineffective. Never take St. John’s wort while using Bosulif.

Over-the-counter medications: Check with your pharmacist or doctor before taking any new over-the-counter drugs, especially:

• Proton pump inhibitors (PPIs) for heartburn/reflux
• Nonsteroidal anti-inflammatory drugs (NSAIDs) if you have low platelet counts
• Herbal supplements or vitamins (some may interact with Bosulif)

Activities requiring precautions:

Sun exposure: Some patients experience increased sun sensitivity while taking Bosulif. Wear protective clothing and sunscreen (SPF 30 or higher) when outdoors. Limit prolonged sun exposure, especially during peak hours.

Contact sports and activities with injury risk: Because Bosulif can lower platelet counts (increasing bleeding risk), discuss any high-impact sports or activities with your healthcare provider. You may need to avoid activities with significant injury or bleeding risk if your platelet count is low.

Elective surgery and dental procedures: Inform your surgeon or dentist that you’re taking Bosulif. Your doctor may temporarily stop Bosulif before planned procedures due to bleeding risk or need for anesthesia interactions.

Pregnancy and breastfeeding:

Pregnancy: Bosulif can harm an unborn baby and should not be used during pregnancy. Women of childbearing potential must use effective contraception during treatment and for at least 2 weeks after the last dose. Men with partners who can become pregnant should also use contraception during treatment and for at least 3 months after the last dose.

Breastfeeding: Do not breastfeed while taking Bosulif and for at least 2 weeks after your last dose, as bosutinib may pass into breast milk.

Infections and vaccinations:

Avoid exposure to infections: Bosulif can lower your white blood cell count, making you more susceptible to infections. Practice good hand hygiene, avoid crowds during cold/flu season, and stay away from people who are sick.

Live vaccines: Discuss vaccinations with your healthcare provider before receiving any vaccines while taking Bosulif. Live vaccines may not be safe for immunocompromised patients.

Driving and operating machinery:

Bosulif can cause fatigue, dizziness, or visual disturbances in some patients. If you experience these side effects, avoid driving or operating heavy machinery until you know how the medication affects you.

No, Bosulif (bosutinib) can cause serious harm to an unborn baby and should not be used during pregnancy. Women who are pregnant or planning to become pregnant should not take Bosulif.

Why Bosulif is not safe during pregnancy:

Bosulif is classified as a pregnancy category drug that may cause fetal harm based on animal studies and the mechanism of action. Tyrosine kinase inhibitors like bosutinib can interfere with fetal development and may cause birth defects or pregnancy loss.

Pregnancy testing and contraception requirements:

Before starting Bosulif: Women of childbearing potential must have a negative pregnancy test before beginning Bosulif treatment.

During treatment: Effective contraception (birth control) is required throughout Bosulif treatment and for at least 2 weeks after your last dose. Discuss contraception options with your healthcare provider to ensure you’re using a reliable method.

For male patients: Men taking Bosulif who have partners who could become pregnant should use effective contraception during treatment and for at least 3 months after the last dose.

If you become pregnant while taking Bosulif:

Contact your healthcare provider immediately if you become pregnant or think you may be pregnant while taking Bosulif (bosutinib). Do not stop taking Bosulif without first talking to your doctor, as abruptly stopping treatment for CML could be harmful. Your doctor will help you evaluate the risks and make an informed decision about your treatment.

Managing CML during pregnancy:

If you’re diagnosed with CML while pregnant or want to become pregnant while being treated for CML, work closely with both your oncologist/hematologist and your obstetrician. In some cases, CML treatment may need to be delayed until after delivery if the disease is stable. In other situations, alternative treatments that may be safer during pregnancy might be considered.

Fertility considerations:

Discuss fertility preservation options with your healthcare provider before starting Bosulif if you plan to have children in the future. While Bosulif’s effects on fertility are not fully known, it’s important to understand your options for preserving fertility before beginning treatment.

Breastfeeding while taking Bosulif:

Do not breastfeed while taking Bosulif and for at least 2 weeks after your last dose. Bosutinib may pass into breast milk and could harm a nursing baby.

Proper handling and storage of Bosulif (bosutinib) ensures the medication remains effective and safe throughout your treatment.

Storage instructions for Bosulif (bosutinib):

Temperature: Store Bosulif tablets at room temperature between 68°F to 77°F (20°C to 25°C). Brief temperature excursions between 59°F to 86°F (15°C to 30°C) are acceptable, but avoid prolonged exposure to extreme temperatures.

Container: Keep Bosulif tablets in their original container with the lid tightly closed. The original packaging is designed to protect the medication from moisture and light.

Location: Store in a dry place away from moisture, heat, and direct sunlight. Do not store in bathrooms or near sinks where the medication might be exposed to moisture.

Keep out of reach: Store Bosulif in a secure location out of reach of children and pets. This is a potent medication that can be harmful if accidentally ingested.

Safe handling of Bosulif (bosutinib):

Taking your dose: Handle Bosulif tablets as you would any oral medication. Wash your hands after handling tablets if you touch them directly.

For caregivers: If you’re handling Bosulif tablets for someone else (such as a family member or patient), wash your hands thoroughly before and after handling the medication. If you’re pregnant or planning to become pregnant, use caution when handling Bosulif tablets and consider wearing disposable gloves.

If tablets are damaged: Do not take broken, crushed, or damaged Bosulif tablets. If your tablets arrive damaged or break during handling, contact your pharmacy for replacement tablets. Do not try to use damaged tablets as this can affect dosing accuracy and may increase side effect risks.

Traveling with Bosulif (bosutinib):

Carry-on luggage: When traveling by air, keep Bosulif in your carry-on luggage rather than checked baggage to maintain proper temperature and ensure you have access to your medication. Extreme temperatures in airplane cargo holds can affect medication stability.

Prescription label: Keep Bosulif in its original labeled container when traveling to avoid issues with airport security or customs. Carry a copy of your prescription if traveling internationally.

Time zones: If crossing time zones, work with your healthcare provider to adjust your dosing schedule to maintain consistent 24-hour intervals between doses.

Medication supply: Ensure you have adequate supply for your entire trip plus a few extra days in case of travel delays. QuickRx can help coordinate early refills before extended travel.

Disposal of unused or expired Bosulif:

Do not flush: Never flush Bosulif tablets down the toilet or pour them down a drain unless specifically instructed to do so.

Medication take-back programs: The safest way to dispose of unused Bosulif is through a medication take-back program. Contact your local pharmacy, law enforcement agency, or waste management authority to find take-back locations near you.

Household disposal: If no take-back program is available, you may dispose of Bosulif in household trash by following these FDA recommendations:

• Mix tablets with an unpalatable substance like dirt, cat litter, or used coffee grounds
• Place the mixture in a sealed container or plastic bag
• Remove or obscure personal information on the prescription label
• Dispose of the container in household trash

Refill management:

QuickRx Specialty Pharmacy tracks your refill schedule and contacts you before you need your next Bosulif supply. We coordinate with your insurance and copay assistance programs to ensure uninterrupted treatment. We also provide medication counseling and support throughout your therapy.

Regular monitoring is essential while taking Bosulif (bosutinib) to ensure the medication is working effectively, detect any side effects early, and adjust treatment as needed.

Blood tests required during Bosulif treatment:

Complete blood count (CBC): Your doctor will check your white blood cell count, red blood cell count (hemoglobin/hematocrit), and platelet count regularly. These tests detect myelosuppression (low blood counts), which is a common side effect of Bosulif.

• During the first 3 months: CBC typically every 1-2 weeks
• After 3 months: CBC monthly or as clinically indicated
• With dose changes or low counts: More frequent monitoring may be needed

Liver function tests: Bosulif can cause elevated liver enzymes or liver damage, so regular monitoring of liver function is critical.

• During the first 3 months: Monthly liver function tests
• After 3 months: Every 3 months or as clinically indicated
• If enzymes are elevated: More frequent monitoring until values normalize

Tests include: ALT (alanine aminotransferase), AST (aspartate aminotransferase), alkaline phosphatase, and bilirubin.

Kidney function tests: Your healthcare provider will monitor kidney function periodically, especially if you’re at risk for kidney problems or taking other medications that affect the kidneys.

Disease monitoring tests:

BCR-ABL transcript levels: Quantitative PCR blood tests measure the level of BCR-ABL, the abnormal protein that drives CML. This highly sensitive test tracks your molecular response to Bosulif.

• Frequency: Typically every 3 months during the first year, then at least every 3-6 months once stable
• Purpose: Confirms Bosulif is effectively suppressing CML and detects early signs of treatment resistance

Bone marrow examination: Bone marrow aspiration and biopsy assess cytogenetic response by looking for Philadelphia chromosome-positive cells.

• Timing: At baseline, 3 months, 6 months, 12 months, then annually or as needed
• Purpose: Provides detailed assessment of CML response and detects any progression

Heart monitoring:

Electrocardiogram (ECG): Bosulif may cause QT interval prolongation, a heart rhythm abnormality that can be serious.

• Baseline ECG: Before starting Bosulif
• Follow-up ECGs: During treatment, especially if you have risk factors for QT prolongation or take other QT-prolonging medications
• If QT prolongation occurs: Your doctor may reduce your Bosulif dose or switch treatments

Other monitoring considerations:

Blood pressure: Monitor blood pressure regularly, as some tyrosine kinase inhibitors can affect cardiovascular health.

Weight and fluid status: Report any sudden weight gain or swelling, as Bosulif can cause fluid retention in some patients.

Symptom monitoring: Keep track of any new or worsening symptoms between visits, including:

• Unusual fatigue or weakness
• Signs of infection (fever, chills, sore throat)
• Unusual bleeding or bruising
• Severe or persistent diarrhea, nausea, or vomiting
• Yellowing of skin or eyes
• Chest pain or irregular heartbeat
• Shortness of breath or difficulty breathing
• Severe abdominal pain

Importance of keeping appointments:

Regular monitoring appointments are crucial for safe and effective Bosulif treatment. These tests help your healthcare team:

• Confirm Bosulif is controlling your CML effectively
• Detect side effects before they become serious
• Adjust your dose if needed
• Identify treatment resistance early
• Maintain your quality of life during treatment

If you miss a monitoring appointment, contact your healthcare provider to reschedule as soon as possible. Never skip blood tests or monitoring visits, even if you’re feeling well.

QuickRx Specialty Pharmacy coordinates with your healthcare team to ensure you have continuous access to Bosulif (bosutinib) and maintains your copay assistance throughout treatment. We provide refill reminders and support to help you stay on track with your monitoring schedule.

While many side effects of Bosulif (bosutinib) are manageable, some symptoms require immediate medical attention. Knowing when and how to seek help ensures your safety during treatment.

Seek emergency medical care immediately for:

Signs of severe allergic reaction:

• Difficulty breathing or swallowing
• Swelling of the face, lips, tongue, or throat
• Severe rash or hives
• Rapid heartbeat with dizziness

Signs of severe bleeding:

• Vomiting blood or material that looks like coffee grounds
• Coughing up blood
• Blood in urine or stool (red or black, tarry stools)
• Severe or uncontrollable bleeding from any site
• Sudden severe headache or confusion (possible brain bleeding)

Cardiac symptoms:

• Severe chest pain or pressure
• Irregular heartbeat or palpitations with dizziness
• Fainting or near-fainting
• Severe shortness of breath

Severe gastrointestinal symptoms:

• Severe abdominal pain that doesn’t improve
• Persistent vomiting preventing you from keeping down food, fluids, or medication
• Severe diarrhea (more than 6-8 episodes per day) despite anti-diarrheal medication
• Signs of severe dehydration (extreme thirst, no urination, confusion, severe weakness)

Contact your healthcare provider promptly for:

Signs of liver problems:

• Yellowing of skin or whites of eyes (jaundice)
• Dark amber-colored urine
• Pale or clay-colored stools
• Severe fatigue or weakness
• Loss of appetite lasting several days
• Nausea or vomiting that persists
• Pain in the upper right side of your abdomen

Signs of infection (due to low white blood cell count):

• Fever of 100.4°F (38°C) or higher
• Chills or sweating
• Sore throat or mouth sores
• Cough or shortness of breath
• Burning or pain with urination
• Redness, swelling, or pain at any wound site

Signs of low platelet count:

• Easy or unusual bruising
• Small red or purple spots on skin (petechiae)
• Prolonged bleeding from cuts
• Nosebleeds that don’t stop with pressure
• Heavy or prolonged menstrual periods

Signs of severe fluid retention:

• Rapid weight gain (more than 3-5 pounds in a few days)
• Severe swelling in legs, feet, or abdomen
• Shortness of breath when lying down

Managing common side effects at home:

For mild to moderate side effects that don’t require emergency care:

Diarrhea: Take anti-diarrheal medication as recommended by your doctor (such as loperamide), stay well-hydrated, eat bland foods, and avoid dairy, fatty, or spicy foods. Contact your doctor if diarrhea persists despite these measures.

Nausea: Take anti-nausea medication as prescribed, eat small frequent meals, avoid strong odors, and stay hydrated with clear fluids. Taking Bosulif with food often helps reduce nausea.

Fatigue: Balance activity with rest, maintain good sleep habits, eat nutritious foods, and stay moderately active as tolerated. Report severe or worsening fatigue to your doctor.

Rash or skin changes: Use gentle, fragrance-free skincare products, avoid hot showers, apply moisturizer regularly, and protect skin from sun exposure. Contact your doctor if rash is severe, spreading, or accompanied by other symptoms.

Dose modifications for side effects:

Your healthcare provider may temporarily stop Bosulif, reduce your dose, or slow your dose escalation schedule if you experience significant side effects. Once side effects resolve or improve, you may resume Bosulif at the same or a lower dose. Never adjust your Bosulif dose or stop taking it without consulting your healthcare provider first.

QuickRx support for managing side effects:

QuickRx Specialty Pharmacy provides:

• 24/7 pharmacist access for urgent medication questions
• Side effect management counseling
• Coordination with your healthcare team for dose adjustments
• Support medications for symptom management (anti-diarrheal, anti-nausea)
• Ongoing monitoring and check-ins throughout your treatment

Call (917) 830-2525 or (800) 496-6111 anytime if you have concerns about side effects from Bosulif (bosutinib). If you’re experiencing a medical emergency, call 911 or go to the nearest emergency room immediately.

The medical information on this page is sourced from peer-reviewed clinical references and authoritative medical databases to ensure accuracy and reliability. QuickRx Specialty Pharmacy is committed to providing evidence-based information about Bosulif (bosutinib) copay assistance and chronic myeloid leukemia treatment.

REFERENCES:
1. Bosulif (bosutinib) [prescribing information]. Pfizer Inc.
2. UpToDate: Bosutinib: Drug information. Available at: https://www.uptodate.com
3. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia. Available at: https://www.nccn.org
4. American Cancer Society: Treating Chronic Myeloid Leukemia. Available at: https://www.cancer.org
5. Leukemia & Lymphoma Society: Chronic Myeloid Leukemia (CML). Available at: https://www.lls.org

DISCLAIMER:
This page provides general information about Bosulif (bosutinib) copay assistance programs and is not a substitute for professional medical advice. Always consult your healthcare provider for medical guidance specific to your condition. QuickRx Specialty Pharmacy does not provide medical advice, diagnosis, or treatment recommendations.

QuickRx is a nationwide specialty pharmacy licensed in all 50 states, dedicated to helping patients afford life-saving medications. Contact us today to learn how much you can save on Bosulif (bosutinib) copay assistance.

Last reviewed: November 2025